The unique history of Wilson Sonsini Goodrich & Rosati closely traces the birth and evolution of Silicon Valley.
For more than 60 years, Wilson Sonsini has represented technology pioneers associated with virtually every milestone innovation, as well as life sciences trailblazers shaping the future of healthcare.
Today, the firm is synonymous with ushering promising, innovative companies through their business life cycle.
Careers
We look for the best and brightest of tomorrow and develop careers from the ground up.
News and Featured Insights
Leading Matters
Client Highlights
Firm Advises ON.energy on Partnership with Crusoe
On July 21, 2026, Crusoe, the artificial intelligence (AI) factory company, and ON.energy, a company dedicated to building energy and AI infrastructure, announced a partnership to deploy 5 gigawatts of AI UPS™ technology across multiple hyperscale campuses. Commissioning will commence in 2026 and extend into 2027. Wilson Sonsini Goodrich & Rosati advised ON.energy on the transaction.
Client Highlights
Wilson Sonsini Advises Freenome on IP Matters Related to Business Combination, Public Company Launch
On July 20, 2026, Freenome Holdings, Inc. (Freenome), an early cancer detection company developing blood-based screening tests, announced the closing of its previously announced business combination with Perceptive Capital Solutions Corp. (PCSC). The combined company is renamed Freenome, Inc., and its common stock commenced trading on the Nasdaq Capital Market on July 21, 2026, under the new ticker symbol “FRNM.” Wilson Sonsini Goodrich & Rosati advised Freenome on IP matters related to the transaction.
Freenome's Personalized Cancer Detection (PCD) approach to screening combines multiomic blood-based tests with integrated digital solutions to help providers identify eligible patients and deliver guideline-based screening for each individual based on their health profile. The company will use the proceeds from this transaction to support its mission of making early cancer detection simple, accessible, and personalized.
The Wilson Sonsini team that advised Freenome on IP matters related to the transaction included Ali Alemozafar, Dawson Wong, Matthew Garnica, and Grace Liu.
For more information, please see Freenome’s news release.
Freenome's Personalized Cancer Detection (PCD) approach to screening combines multiomic blood-based tests with integrated digital solutions to help providers identify eligible patients and deliver guideline-based screening for each individual based on their health profile. The company will use the proceeds from this transaction to support its mission of making early cancer detection simple, accessible, and personalized.
The Wilson Sonsini team that advised Freenome on IP matters related to the transaction included Ali Alemozafar, Dawson Wong, Matthew Garnica, and Grace Liu.
For more information, please see Freenome’s news release.
Client Highlights
Wilson Sonsini Advises Straiker on Series A
On June 29, 2026, Straiker, an agentic security company, announced the completion of its Series A round, bringing its total funding to $85 million. The financing was led by Marathon Management Partners, Citi Ventures, Illuminate Financial, and Workday Ventures, with continued support from Bain Capital Ventures and Lightspeed. Other investors include GTM Capital, Rain Capital, Neva SGR, Firebolt Ventures, and Sixty Degree Ventures. Wilson Sonsini Goodrich & Rosati advised Straiker on the transaction.
Client Highlights
Wilson Sonsini Advises Crypto.com on $400 Million Strategic Investment by Citadel
On July 16, 2026, Crypto.com announced a strategic $400 million investment from Citadel Securities, valuing the company at $20 billion. Wilson Sonsini Goodrich & Rosati advised Crypto.com on the transaction. Funding is expected to accelerate Crypto.com's expansion into all asset classes, including tokenized securities and derivatives. The milestone marks the first institutional funding round in the company's decade-long history.
Client Highlights
Wilson Sonsini Advises DataPelago on Acquisition by NetApp
On July 16, 2026, NetApp® announced it has acquired DataPelago, a California-based AI data infrastructure company. Wilson Sonsini Goodrich & Rosati advised DataPelago on the transaction.
Client Highlights
Wilson Sonsini Advises NIPRO on Expanded Partnership with Linear Health Sciences
On July 13, 2026, Linear Health Sciences announced that Japanese medical device manufacturer NIPRO will begin distributing its Orchid Safety Release Valve (SRV) in the Japanese market beginning July 22, 2026. The device is designed to prevent unintentional IV catheter dislodgement by introducing a mechanism that safely disconnects when excessive force is applied. Wilson Sonsini Goodrich & Rosati advised NIPRO on the transaction.
The Life Sciences Report – June 2026
This latest edition features articles on accelerating new therapies under the new FDA administration, cash-pay healthcare companies possibly facing kickback and fee-splitting risk under federal and state laws, building in-house legal teams for biotech, digital health, and medical devices companies, and life sciences venture financings for firm clients across 1H2025.